Guerbet restructuring affects profit

Article

French contrast agent developer Guerbet in March released financial results for 1998, which the company characterized as a rebuilding year. Guerbet enjoyed slightly higher revenues for the period, posting sales of FFr 1.15 billion ($187.5 million), up 3%

French contrast agent developer Guerbet in March released financial results for 1998, which the company characterized as a rebuilding year. Guerbet enjoyed slightly higher revenues for the period, posting sales of FFr 1.15 billion ($187.5 million), up 3% compared with FFr 1.12 billion ($182.3 million) in 1997. But the company’s bottom line swung into the red, with Guerbet recording a net loss of $10.8 million, compared with a net profit of $10.7 million the prior year.

Guerbet embarked on a stringent restructuring program in 1998 to counter increased competition and price pressures in its primary markets, which are mainly x-ray contrast media. The restructuring included a 10% workforce cut. Guerbet said that it expects to return to profitability in 1999.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.